Loading…
In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines
Background: Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key...
Saved in:
Published in: | British journal of cancer 2011-07, Vol.105 (3), p.393-402 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273 |
---|---|
cites | cdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273 |
container_end_page | 402 |
container_issue | 3 |
container_start_page | 393 |
container_title | British journal of cancer |
container_volume | 105 |
creator | Adhim, Z Matsuoka, T Bito, T Shigemura, K Lee, K-M Kawabata, M Fujisawa, M Nibu, K Shirakawa, T |
description | Background:
Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells.
Methods:
We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the
in vivo
study.
Results:
Within the clinical drug concentrations, only etodolac showed the
in vitro
growth inhibition in T24 not in the other cell lines. Etodolac reduced
SNAIL
mRNA and vimentin cell surface expression, and induced
E-cadherin
mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24
in vitro
and showed the highest tumour growth inhibition in T24 tumour
in vivo
.
Conclusion:
Etodolac at clinical doses exhibited induced
in vitro
and
in vivo
anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer. |
doi_str_mv | 10.1038/bjc.2011.262 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3172915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2408052521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</originalsourceid><addsrcrecordid>eNptkU2LFDEQhoMo7jh68yxBEC_2mKQ_c1mQwY-FBS96Dumksp0hnYxJ9-D8B3-0aWfcUfFUFPXkzVv1IvSckg0lZfe236kNI5RuWMMeoBWtS1bQjrUP0YoQ0haEM3KFnqS0yy0nXfsYXTHa1qSuyQr9uPH4YKcYsPQa26U5hFwH29spxCMGY0BNOBg8DREAb8P3gl2A9Osd7O00gLPSFVMoRkjg1XAcpcNTlD7ZyQa_iA_zKD3undQaIlbSq6WAc9hZD-kpemSkS_DsXNfo64f3X7afitvPH2-2724LVVfVVFAGQGVDVcc16zvgpGlqTWquSsVBk1IZw6ihqpJaaWm0rkqmuWmJNh1nbblG1yfd_dyPoBX4bNOJfbSjjEcRpBV_T7wdxF04iJK2jOcLr9Hrs0AM32ZIkxhtWvaQHsKcRNfypm1IW2by5T_kLszR5-0WiLKa8wV6c4JUDClFMPdWKBFLyCKHLJaQRQ454y_-tH8P_041A6_OgExKOpMzUDZduKqiPF8yc8WJS3nk7yBezP334593e8HE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879125993</pqid></control><display><type>article</type><title>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</title><source>PubMed Central Free</source><creator>Adhim, Z ; Matsuoka, T ; Bito, T ; Shigemura, K ; Lee, K-M ; Kawabata, M ; Fujisawa, M ; Nibu, K ; Shirakawa, T</creator><creatorcontrib>Adhim, Z ; Matsuoka, T ; Bito, T ; Shigemura, K ; Lee, K-M ; Kawabata, M ; Fujisawa, M ; Nibu, K ; Shirakawa, T</creatorcontrib><description>Background:
Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells.
Methods:
We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the
in vivo
study.
Results:
Within the clinical drug concentrations, only etodolac showed the
in vitro
growth inhibition in T24 not in the other cell lines. Etodolac reduced
SNAIL
mRNA and vimentin cell surface expression, and induced
E-cadherin
mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24
in vitro
and showed the highest tumour growth inhibition in T24 tumour
in vivo
.
Conclusion:
Etodolac at clinical doses exhibited induced
in vitro
and
in vivo
anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2011.262</identifier><identifier>PMID: 21750550</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/80/84/2176 ; 631/92/436/2388 ; 692/308/575 ; 692/699/67/589/1336 ; Animals ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Bladder cancer ; Cadherins - metabolism ; Cancer Research ; Cell Dedifferentiation ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cyclooxygenase 2 Inhibitors - pharmacology ; Drug Resistance ; Epidemiology ; Epithelial-Mesenchymal Transition ; Etodolac - pharmacology ; Humans ; Medical sciences ; Mice ; Mice, Nude ; Molecular Medicine ; Nephrology. Urinary tract diseases ; Oncology ; Translational Therapeutics ; Tumors ; Tumors of the urinary system ; Urinary Bladder Neoplasms ; Urinary tract. Prostate gland ; Vimentin - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>British journal of cancer, 2011-07, Vol.105 (3), p.393-402</ispartof><rights>The Author(s) 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jul 26, 2011</rights><rights>Copyright © 2011 Cancer Research UK 2011 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</citedby><cites>FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172915/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172915/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24419544$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21750550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adhim, Z</creatorcontrib><creatorcontrib>Matsuoka, T</creatorcontrib><creatorcontrib>Bito, T</creatorcontrib><creatorcontrib>Shigemura, K</creatorcontrib><creatorcontrib>Lee, K-M</creatorcontrib><creatorcontrib>Kawabata, M</creatorcontrib><creatorcontrib>Fujisawa, M</creatorcontrib><creatorcontrib>Nibu, K</creatorcontrib><creatorcontrib>Shirakawa, T</creatorcontrib><title>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells.
Methods:
We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the
in vivo
study.
Results:
Within the clinical drug concentrations, only etodolac showed the
in vitro
growth inhibition in T24 not in the other cell lines. Etodolac reduced
SNAIL
mRNA and vimentin cell surface expression, and induced
E-cadherin
mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24
in vitro
and showed the highest tumour growth inhibition in T24 tumour
in vivo
.
Conclusion:
Etodolac at clinical doses exhibited induced
in vitro
and
in vivo
anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.</description><subject>631/80/84/2176</subject><subject>631/92/436/2388</subject><subject>692/308/575</subject><subject>692/699/67/589/1336</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bladder cancer</subject><subject>Cadherins - metabolism</subject><subject>Cancer Research</subject><subject>Cell Dedifferentiation</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cyclooxygenase 2 Inhibitors - pharmacology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Etodolac - pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Molecular Medicine</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oncology</subject><subject>Translational Therapeutics</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms</subject><subject>Urinary tract. Prostate gland</subject><subject>Vimentin - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNptkU2LFDEQhoMo7jh68yxBEC_2mKQ_c1mQwY-FBS96Dumksp0hnYxJ9-D8B3-0aWfcUfFUFPXkzVv1IvSckg0lZfe236kNI5RuWMMeoBWtS1bQjrUP0YoQ0haEM3KFnqS0yy0nXfsYXTHa1qSuyQr9uPH4YKcYsPQa26U5hFwH29spxCMGY0BNOBg8DREAb8P3gl2A9Osd7O00gLPSFVMoRkjg1XAcpcNTlD7ZyQa_iA_zKD3undQaIlbSq6WAc9hZD-kpemSkS_DsXNfo64f3X7afitvPH2-2724LVVfVVFAGQGVDVcc16zvgpGlqTWquSsVBk1IZw6ihqpJaaWm0rkqmuWmJNh1nbblG1yfd_dyPoBX4bNOJfbSjjEcRpBV_T7wdxF04iJK2jOcLr9Hrs0AM32ZIkxhtWvaQHsKcRNfypm1IW2by5T_kLszR5-0WiLKa8wV6c4JUDClFMPdWKBFLyCKHLJaQRQ454y_-tH8P_041A6_OgExKOpMzUDZduKqiPF8yc8WJS3nk7yBezP334593e8HE</recordid><startdate>20110726</startdate><enddate>20110726</enddate><creator>Adhim, Z</creator><creator>Matsuoka, T</creator><creator>Bito, T</creator><creator>Shigemura, K</creator><creator>Lee, K-M</creator><creator>Kawabata, M</creator><creator>Fujisawa, M</creator><creator>Nibu, K</creator><creator>Shirakawa, T</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110726</creationdate><title>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</title><author>Adhim, Z ; Matsuoka, T ; Bito, T ; Shigemura, K ; Lee, K-M ; Kawabata, M ; Fujisawa, M ; Nibu, K ; Shirakawa, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/80/84/2176</topic><topic>631/92/436/2388</topic><topic>692/308/575</topic><topic>692/699/67/589/1336</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bladder cancer</topic><topic>Cadherins - metabolism</topic><topic>Cancer Research</topic><topic>Cell Dedifferentiation</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cyclooxygenase 2 Inhibitors - pharmacology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Etodolac - pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Molecular Medicine</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oncology</topic><topic>Translational Therapeutics</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms</topic><topic>Urinary tract. Prostate gland</topic><topic>Vimentin - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adhim, Z</creatorcontrib><creatorcontrib>Matsuoka, T</creatorcontrib><creatorcontrib>Bito, T</creatorcontrib><creatorcontrib>Shigemura, K</creatorcontrib><creatorcontrib>Lee, K-M</creatorcontrib><creatorcontrib>Kawabata, M</creatorcontrib><creatorcontrib>Fujisawa, M</creatorcontrib><creatorcontrib>Nibu, K</creatorcontrib><creatorcontrib>Shirakawa, T</creatorcontrib><collection>SpringerOpen (Open Access)</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adhim, Z</au><au>Matsuoka, T</au><au>Bito, T</au><au>Shigemura, K</au><au>Lee, K-M</au><au>Kawabata, M</au><au>Fujisawa, M</au><au>Nibu, K</au><au>Shirakawa, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2011-07-26</date><risdate>2011</risdate><volume>105</volume><issue>3</issue><spage>393</spage><epage>402</epage><pages>393-402</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells.
Methods:
We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the
in vivo
study.
Results:
Within the clinical drug concentrations, only etodolac showed the
in vitro
growth inhibition in T24 not in the other cell lines. Etodolac reduced
SNAIL
mRNA and vimentin cell surface expression, and induced
E-cadherin
mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24
in vitro
and showed the highest tumour growth inhibition in T24 tumour
in vivo
.
Conclusion:
Etodolac at clinical doses exhibited induced
in vitro
and
in vivo
anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21750550</pmid><doi>10.1038/bjc.2011.262</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 2011-07, Vol.105 (3), p.393-402 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3172915 |
source | PubMed Central Free |
subjects | 631/80/84/2176 631/92/436/2388 692/308/575 692/699/67/589/1336 Animals Antineoplastic Agents - pharmacology Apoptosis - drug effects Biological and medical sciences Biomedical and Life Sciences Biomedicine Bladder cancer Cadherins - metabolism Cancer Research Cell Dedifferentiation Cell Line, Tumor Cell Proliferation - drug effects Cyclooxygenase 2 Inhibitors - pharmacology Drug Resistance Epidemiology Epithelial-Mesenchymal Transition Etodolac - pharmacology Humans Medical sciences Mice Mice, Nude Molecular Medicine Nephrology. Urinary tract diseases Oncology Translational Therapeutics Tumors Tumors of the urinary system Urinary Bladder Neoplasms Urinary tract. Prostate gland Vimentin - metabolism Xenograft Model Antitumor Assays |
title | In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A38%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20and%20in%20vivo%20inhibitory%20effect%20of%20three%20Cox-2%20inhibitors%20and%20epithelial-to-mesenchymal%20transition%20in%20human%20bladder%20cancer%20cell%20lines&rft.jtitle=British%20journal%20of%20cancer&rft.au=Adhim,%20Z&rft.date=2011-07-26&rft.volume=105&rft.issue=3&rft.spage=393&rft.epage=402&rft.pages=393-402&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2011.262&rft_dat=%3Cproquest_pubme%3E2408052521%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=879125993&rft_id=info:pmid/21750550&rfr_iscdi=true |